Chapter 25: Drugs for Alzheimer Disease

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Imagine looking at a patient who has just forgotten their spouse's name for the very first time.

I mean, it's a devastating moment.

It really is.

But what if I told you the physiological damage that actually paused that specific moment

started 20 years ago, completely in silence?

Yeah, it's a staggering reality of neurodegeneration.

You've got two decades of silent microscopic buildup before a single outward symptom ever even appears.

Right, which that time scale completely changes how we have to think about this disease.

So welcome to a very special session from the Last Minute Lecture.

I'm glad you're here.

If you are a nursing student listening to this deep dive right now, we know you're staring down exams, clinical rotations, and, you know, a mountain of pharmacology.

How much pharmacology?

Exactly.

So our mission today is to help you completely master Chapter 25, Drugs for Alzheimer Disease from Lenz Pharmacology for Nursing Care.

We're going to distill this down so you are fundamentally ready to understand the mechanisms, pass your exams, and advocate for your patients safely.

Let's ground ourselves in the big picture first.

So Alzheimer disease, or AD,

it's characterized by progressive memory loss, impaired thinking, and profound neuropsychiatric symptoms like hallucinations and delusions.

Which is terrifying for the patient and the family.

Totally.

And ultimately, it strips away the ability to perform basic activities of daily living.

It currently affects an estimated 6 .5 million older Americans.

That makes it the sixth leading cause of death.

And the financial toll is insane.

Right, yeah.

It costs the health care system about $321 billion annually.

Wow.

Okay, but the textbook hits us with the hard truth right up front, and we need to face it before we even look at a single medication.

The neuronal damage occurring in the brain is irreversible.

Yes.

I mean, the core pharmacological reality of this chapter is that current drugs cannot cure Alzheimer's disease.

They do incredibly little to relieve the symptoms, and for many patients, they do not significantly delay the overall progression of the disease or the cognitive decline.

That is, I mean, that's heavy.

But to understand how our limited pharmacological tools are even attempting to work, we have to look under the hood.

Like, how does this neuronal degeneration actually move through the brain geographically?

Well, the destruction follows a progressive spread.

So early in the disease,

neuronal degeneration targets the hippocampus.

And the hippocampus is short -term memory, right?

Exactly.

Because it serves an essential role in forming short -term memories, its degradation leads to the very first noticeable signs of the disease, which is failing short -term memory.

Okay, and then the damage eventually creeps outward, right, into the cerebral cortex.

Yeah, it moves to the cortex, which is the central hub for speech, perception, reasoning, and higher -level functions.

So as those cortical neurons degenerate, patients lose their language skills and advance the timeline even further, and you see the loss of bowel and bladder control, a complete inability for self -care,

and, you know, eventually the destruction of enough brain function to cause death.

It's relentless.

And when we look at the neurotransmitters, the sheer scale of the loss detailed in the text is shocking.

In advanced AD, acetylcholine levels are 90 % below normal.

90%.

I mean, a 90 % drop in a brain chemical seems like it should be the sole culprit for the memory loss, considering acetylcholine is critical for forming those memories.

It seems obvious, right?

But we have to decouple cause and effect here.

The text points out a major caveat.

In patients with only mild AD, their cholinergic transmission is actually essentially normal.

Wait, really?

Yeah.

That massive drop in acetylcholine happens later.

Therefore, a lack of acetylcholine alone cannot explain those early cognitive deficits we see when the patient first shows up at the clinic.

So if the neurotransmitters dropping is a later effect, what is the actual primary source of the destruction?

I mean, the chapter points to the hallmarks of the disease found under a microscope, which are neuritic plaques and neurofibrillary tangles.

Right.

Let's start with the attack happening outside the neurons.

This involves the neuritic plaques.

These are spherical bodies found mainly in the hippocampus and the cerebral cortex.

And they're made of what, exactly?

They have a central core made of beta amyloid, which is a toxic protein fragment, and they are surrounded by the remnants of dead neurons.

This is that silent accumulation we mentioned earlier, beginning 10 to 20 years before the first clinical symptoms appear.

That is the external debris field, basically.

Yeah.

But the text also describes neurofibrillary tangles attacking from the inside of the neuron.

I like to think of a healthy neuron like a massive manufacturing plant.

That's a great analogy.

Yeah.

Inside, you have a protein called tau.

Tau proteins act like the sturdy railroad ties on the internal tracks that deliver nutrients from the center of the cell all the way out to the edges.

But in Alzheimer's pathology, something causes that tau protein to become abnormal.

It twists into paired helical filaments, so your railroad ties warp and buckle.

The tracks just tangle up completely.

Exactly.

The supply chain halts, and the neuron literally starves to death from the inside out.

So we have plaques smothering the cell from the outside and tangles starving it from the inside.

Let's tackle a question patients always bring up regarding genetics.

Oh, the APOE4 question.

If a patient gets a DNA test and discovers they have the apolipoprotein E4 gene, or APOE4, is Alzheimer's a mathematical guarantee.

Far from it.

Having one or two copies of the gene associated with APOE4 increases your risk, specifically because that gene variation impairs the brain's ability to clear out that toxic beta amyloid protein.

So the plaques just build up faster.

Right.

However, many people who develop AD do not have the APOE4 gene at all.

And conversely, plenty of people with the gene never develop the disease.

Okay, so if we can't blame it all on genetics, who is actually most susceptible to these physiological changes?

Well, advancing age is the single biggest non -modifiable risk factor.

In 90 % of patients, the onset is 65 years or older.

And by the time you reach age 85, it's what, a third of the population?

Yeah, approximately a third of that population has signs and symptoms consistent with AD.

Family history is another major factor, particularly if a first -degree relative developed dementia early in life.

The textbook then shifts to modifiable risk factors, and it heavily emphasizes cardiovascular health.

Why is vascular health suddenly so important when we are talking about a brain disease?

Because the brain is a massive consumer of energy.

It requires immense continuous blood flow to survive.

Cerebrovascular disease is a major risk factor because microvascular damage starves neurons of oxygen.

So if a patient has hypertension, atherosclerosis, or type 2 diabetes?

Those conditions damage the tiny blood vessels in the brain.

That hypoxic stress accelerates any underlying neurodegenerative process.

In fact, AD is identified at autopsy in about a third of patients who were initially diagnosed with vascular dementia.

Here is a caveat from the text that feels like a tough pill to swallow.

We're constantly told to eat right and exercise to prevent Alzheimer's.

Yeah, the lifestyle advice.

Right.

But Lane states very clearly that while unhealthy sedentary lifestyles increase the risk through cardiovascular damage, there is very little good evidence that healthy lifestyles like specific diets, crossword puzzles, or nutritional supplements actually reduce the risk of developing AD.

Exactly.

As a nurse, you have to guide patients with evidence -based practice.

You encourage exercise and a good diet to protect their heart and blood vessels, which supports overall brain perfusion.

But you cannot ethically promise a patient that eating blueberries and doing daily brain training games will build a shield against Alzheimer's pathology.

No, you can't.

It's just not supported by the data.

So let's walk through what this disease actually looks like as it progresses, based on table 25 .1.

The mild stage starts with memory loss, getting lost in familiar surroundings, and noticeable changes in personality and judgment.

And then the moderate stage brings severe functional decline.

Patients develop difficulty with basic activities of daily living, like feeding and bathing.

This is also when behavioral issues peak, right?

Yes.

Anxiety, pacing, wandering, and sundowning, which is a phenomenon where confusion and agitation severely intensify in the evening hours.

They also begin failing to recognize their own family members.

Which is just heartbreaking.

And the severe stage is complete devastation.

Total loss of speech, loss of appetite leading to severe weight loss, total loss of bowel and bladder control, and complete dependence on caregivers for basic survival.

It's a brutal progression.

With a progression this severe, what is our pharmacological goal?

Well, the dream would be reversing the cognitive decline.

But since that is impossible, our current drugs simply aim to improve the symptoms.

And the challenge we face is that the benefits of these approved drugs are statistically significant in clinical trials, but clinically marginal for the actual human being taking them.

Yes, the textbook uses a fantastic analogy here.

Compares the benefit of these Alzheimer's drugs to taking a daily weight loss medication for six months, only to step on the scale and realize you've lost exactly half a pound.

The scale technically moved, the drug technically worked.

But did that half pound change how your clothes fit or improve your life?

Probably not.

That is why clinical guidelines do not demand that all patients receive drug therapy.

The choice is based entirely on tolerability, ease of use, and financial cost.

Okay, let's dive into the medications we do have, starting with the primary class for cognitive impairment,

the colonesterase inhibitors.

These are approved for mild to moderate AD, with our prototype drug Dunpeazle also carrying an approval for severe AD.

So how are these drugs manipulating the brain chemistry?

They target the enzyme acetylcholinesterase, or AC.

Normally, AC acts like a cleanup crew, breaking down acetylcholin in the synapse after a signal is set.

Right.

These drugs inhibit that enzyme.

By stopping the cleanup crew, they increase the overall availability of acetylcholin at the cholinergic synapses.

The goal is to enhance transmission in whatever central cholinergic neurons have not yet been destroyed by the plaques and tangles.

But if we're artificially increasing acetylcholin, we aren't just increasing it in the brain, it's circulating systemically.

What happens to the rest of the body when acetylcholin levels rise?

You trigger a cascade of peripheral cholinergic adverse effects.

In the gastrointestinal tract, the increased activation causes nausea, vomiting, dyspepsia, and diarrhea.

And in the lungs.

Elevating acetylcholin causes bronchoconstriction?

A nurse must use extreme caution when administering these to a patient with a history of asthma or COPD.

The text highlights a massive cardiovascular nursing alert here, too.

Increased cholinergic activation in the heart causes symptomatic bradycardia.

The heart rate drops, blood pressure drops, the patient gets dizzy, they faint, and they fall.

Which is huge.

For an 80 -year -old patient who is already wandering and confused, giving them a drug that slows their heart and makes them dizzy is an astronomical fracture risk.

So monitoring their heart rate and fall risk is paramount.

If a patient is experiencing syncopal episodes, the provider needs to be notified immediately to consider withdrawing the drug, especially considering the cognitive benefits are so minor to begin with.

Absolutely.

You also have to guard against drug interactions.

Any medication that blocks cholinergic receptors will directly counteract your treatment.

That means strict avoidance of first -generation antihistamines, tricyclic antidepressants, and conventional antipsychotics.

Because of those side effects, the universal dosing strategy for this class is start low and go slow.

You titrate the dose up gradually to the highest tolerable amount to grab whatever cognitive benefit you can while keeping the nausea and bradycardia at bay.

All the drugs in this class offer the same modest benefits, but their individual pharmacokinetic profiles are wildly different.

Let's start with the prototype.

Dunpeazle.

Dunpeazle's defining characteristic is that it is highly protein -bound in the blood, giving it a massive prolonged plasma half -life of 70 hours.

70 hours.

Yeah.

Because of that sluggish clearance, it takes about 15 days of daily dosing just to reach a steady state in the patient's bloodstream.

Wait, if Dunpeazle takes two full weeks to stabilize and takes days to clear from the system, that sounds like a nightmare if a frail patient suddenly develops severe nausea or dizziness.

And as a nursing implication, that's why it's usually given at bedtime.

But also, keep in mind the 23 -milligram tablet must be swallowed whole.

Patients must be taught to rise slowly from a supine position and use guardrails due to that bradycardia fall risk we talked about.

Got it.

So how do we adjust if they simply cannot tolerate the oral dosing?

That brings us to ribostigmine.

It has a different mechanism.

It causes irreversible inhibition of ACE, unlike Dunpeazle's reversible inhibition.

But its main problem with oral dosing is intense GI side effects.

Like how bad?

We are talking about up to 26 % of patients experiencing significant weight loss dropping 7 % or more of their initial body weight.

Losing 7 % of your body weight when you are already a frail older adult with dementia sounds catastrophic.

How can a nurse justify administering a medication with that kind of profile?

Well, you bypass the stomach entirely.

Ribostigmine is uniquely available as a 24 -hour transdermal patch.

Oh, that makes sense.

Yeah, when a nurse applies the patch, the drug absorbs directly into the bloodstream at a steady, consistent rate.

It completely avoids that initial spike in blood concentration you get from swallowing a pill, which drastically reduces the intensity of those GI side effects.

The nursing implications for that patch are critical, though.

You apply a single patch once daily to the chest, upper arm, or back.

You must change the site every single day, and you cannot repeat the same site for at least 14 days to avoid severe skin irritation.

Right.

An added benefit of ribostigmine is that it completely bypasses the hepatic drug metabolizing enzymes.

Therefore, unlike Dunpezel, it lacks any significant drug interactions related to liver metabolism.

The third drug in this class is glantamine.

The text throws in a fun botanical fact here.

This drug is actually extracted from daffodil bulbs.

I love that detail.

Me too.

Yeah.

In terms of tolerability, it sits right in the middle.

The GI complaints are greater than what you see with Dunpezel, but much less than oral rapid dystigmine.

Let's pivot to a patient whose disease has progressed into moderate or severe AD.

The cholinesterase inhibitors are losing their effectiveness.

Do we have another pharmacological mechanism to try?

We do.

We introduce the NMDA receptor antagonists.

The prototype, and currently the only drug in this class, is memantine.

Its mechanism of action is completely different.

It works directly at the NMDA receptor, which is the gateway that regulates how calcium enters a neuron.

To understand how memantine works, we first have to understand how a memory is actually made at the cellular level.

Okay, break it down for us.

Under healthy conditions, an action potential fires and causes a massive burst of the neurotransmitter glutamate to be released.

This glutamate binds to the NMDA receptor.

And when it binds?

It knocks a magnesium ion out of the receptor channel.

That opens the door, allowing a brief, sharp pulse of calcium to flood into the neuron.

That brief spike in calcium is the actual internal cellular signal that creates learning and memory.

So once the glutamate leaves, the magnesium slides back into place and plugs the hole.

Exactly.

But in Alzheimer's pathology, that elegant system breaks down completely.

The diseased neurons develop a slow, constant pathological leak of glutamate.

It constantly oozes into the synapse, keeping the NMDA receptor channel propped open all the time.

Which allows a toxic,

continuous trickle of calcium into the neuron.

That constant trickle creates cellular static, its background noise that overpowers any real memory signals trying to get through.

Worse, too much intracellular calcium is incredibly toxic and eventually leads to neuronal death.

Mammontine acts as the pharmacological solution to that leak.

I picture Mammontine as a very smart bouncer at a nightclub door.

That's perfect.

Right.

When there is just that low -level pathological leak of glutamate, the annoying background static Mammontine stands firmly in the doorway and blocks the calcium from getting in.

It allows the neuron to clear out the excess calcium and normalize.

But when a massive, normal burst of glutamate arrives because the brain is genuinely trying to form a new memory… That concentrated burst is strong enough to physically push Mammontine out of the way.

The bouncer steps aside, the true calcium signal gets through, and the memory forms.

The second the signal is done, Mammontine steps right back into the doorway to block the toxic background leak.

It is an elegant mechanism that allows Mammontine to slow functional decline in moderate to severe AD,

and it is generally very well tolerated.

Adverse effects are remarkably mild, with dizziness or headache occurring in only 5 -7 % of patients.

The nursing implications for administration are very specific, though.

The extended release capsules can be swallowed whole.

If the patient has dysphagia, the nurse can open the capsule and sprinkle the granules onto soft food like applesauce.

But those granules must absolutely never be crushed or chewed.

Destroying the extended release coating will cause a rapid unsafe spike in blood levels.

You also have to monitor for drug interactions, particularly regarding clearance.

If a patient takes sodium bicarbonate or any other drug that alkalinizes their urine, it alters the ionization of Mammontine in the kidneys.

Which is bad.

Very.

It drastically decreases renal excretion, causing the Mammontine to accumulate to toxic levels in the blood.

The clinical monitoring parameters here include watching for sudden increases in seizure activity or cardiovascular events like angina.

Up to this point, every drug we've discussed just tries to optimize the surviving neurons.

They don't touch the underlying pathology.

What about actually going in and clearing out those beta amyloid plaques we talked about at the very beginning?

That is the goal of the newest class of drugs.

The monoclonal antibodies.

The text focuses on aducanumab.

It is an intravenous infusion approved specifically for mild AD.

So the antibody crosses the blood -brain barrier, binds directly to the toxic beta amyloid, and stimulates the patient's own immune system to attack, break down, and clear the plaques.

The follow -up MRI scans for these patients are visually astounding.

They prove that the drug absolutely works to remove the physical plaques from the brain tissue.

But the text reveals a massive counterintuitive catch.

Clearing the physical plaques on an MRI does not necessarily translate into clinical improvement for the patient.

Their memory often continues to decline anyway.

While the clinical benefit remains heavily debated, the safety risks are undeniable.

The primary danger is a condition called ARI, which stands for amyloid -related imaging abnormalities.

In roughly 40 % of patients, the immune system's attack on the plaques causes localized brain edema or microhemorrhages.

40 % is an incredibly high rate for a side effect involving brain swelling and microbleeds.

What is the nursing protocol for managing a risk that severe?

It requires an intense, strict monitoring schedule.

Patients are required to have a baseline MRI before the first infusion.

They must then undergo follow -up MRIs prior to infusions at weeks 5, 7, 9, and 12 to actively scan for silent bleeding.

Wow.

Yeah, and nurses must thoroughly screen the patient's medication list and rule out anyone taking anticoagulants due to the catastrophic bleeding risk.

You're also constantly assessing for clinical symptoms of ARI, which present as sudden headaches, severe confusion, visual disturbances, and dizziness.

We have to address the massive scientific and political controversy surrounding adrucanumab, which is laid out strictly in box 25 .1 of the textbook.

The drug's 2021 approval created an absolute storm.

It really did.

The FDA's own independent scientific advisory panel actually voted against recommending the drug for approval.

They cited two massive Phase III clinical trials that produced directly contradictory findings regarding whether the drug actually improved cognitive function.

But the FDA chose to bypass their advisory panel and approved it anyway, utilizing the accelerated approval pathway.

Because Alzheimer's is a terminal disease lacking effective treatments,

the FDA allowed the use of a surrogate endpoint.

Naming.

Instead of requiring definitive proof that the drug improved memory, they accepted the MRI evidence of plaque removal, operating on the hypothesis that clearing plaques would eventually lead to clinical benefit down the road.

That unprecedented decision led to three members of the FDA advisory committee resigning in protest.

The textbook presents both sides of the resulting fallout.

On one hand,

organizations like the Alzheimer's Association heavily praised the approval, focusing on the sheer hope a new mechanism brought to desperate families.

On the other side, organizations like the American Academy of Neurology raised severe alarms regarding the lack of proven clinical evidence and the staggering financial burden.

The financial numbers detailed in the text are unprecedented.

The medication alone was initially estimated to cost around $56 ,000 a year per patient.

And that does not factor in the cost of the facility time for IV administration or the immense cost of those five mandatory MRIs in the first year.

Exactly.

An analysis published in the Journal of the American Medical Association estimated that if Medicare covered just 25 % of eligible patients, it could cost the program up to $37 .4 billion in a single year.

The concern was that one single drug with questionable clinical benefit could literally bankrupt the Medicare system.

It is a profound example of how a nurse's pharmacological knowledge must eventually intersect with healthcare economics and regulatory policy.

Before we wrap up, there is one final crucial aspect of Alzheimer's care we have to touch on.

The memory loss gets all the attention, but over 80 % of 80 patients will eventually develop neuropsychiatric symptoms.

Agitation, aggression, wandering, delusions.

These symptoms threaten the physical safety of the patient, the family caregivers, and the healthcare workers on the floor.

When a patient with dementia suddenly becomes agitated or aggressive,

the absolute first nursing step is to rule out acute underlying physical causes.

Is the patient in unexpressed pain?

Do they have a urinary tract infection?

Are they severely constipated?

And once physical discomfort is ruled out, you must implement non -pharmacological interventions first.

Promote sleep hygiene, utilize music therapy, or introduce pet therapy.

But if the non -pharmacological interventions fail, and the patient is a danger to themselves or others, what medications actually work?

Do the cholinesterase inhibitors or Mementine help calm them down?

They offer virtually zero benefit for neuropsychiatric symptoms.

The pharmacological reality for managing these behaviors is incredibly sobering.

According to the text, the only drugs with convincing clinical evidence for reducing agitation and delusions in AD are the atypical antipsychotics, specifically risperidone and lanzapine.

But those atypical antipsychotics carry a stark black box warning, specifically for older adults with dementia.

They do.

Administering these medications slightly increases the patient's overall mortality rate, mainly driving an increase in sudden cardiovascular events and fatal infections.

Furthermore, the text explicitly states that conventional antipsychotics, mood stabilizers, and benzodiazepines are not recommended.

Their risks of profound sedation, paradoxical agitation, and fall -related fractures far outweigh any minimal behavioral benefits.

So the nurse, the attending provider, and the family are left making an agonizing decision.

You are forced to weigh a marginal improvement in the patient's daily quality of life against a very real, scientifically documented risk of accelerating their death.

It highlights the ultimate responsibility of the nursing profession.

Mastering pharmacology is not just about memorizing side -effect profiles for a multiple -choice test.

It is about understanding the profound physiological implications of these powerful chemicals on a fragile human life.

Which brings us to the end of our chapter outline and leaves us with a final thought to chew on as you hit the books.

We spent this time talking about how the current drugs basically just try to optimize a failing system.

But Adjikanima proved we actually have the technology to go in and literally dissolve the defining pathological hallmark of Alzheimer's disease,

the beta amyloid plaques.

Yet when we wipe the brain clean of those plaques, the patient's memory often does not improve.

Which is wild.

What does that tell us about our fundamental understanding of this disease?

Are the plaques truly the root cause driving the destruction, or are they just the tombstones left behind by a microscopic degenerative process that came and went decades earlier?

It is the ultimate question in neuropharmacology right now, and one that the next generation of researchers and the nurses caring for these patients on the front lines every day will eventually have to answer.

On behalf of the last -minute lecture team, we want to thank you for joining us on this deep dive into chapter 25.

We know nursing pharmacology can feel overwhelming, but understanding the intricate why and how behind these medications makes you not just a better test -taker, but a fundamentally safer, more powerful advocate for your patients.

Best of luck on your upcoming exams.

And even more importantly, best of luck out there in your future clinical practice.

You've got this.